News: Solara Active Pharma Sciences Limited, a prominent pharmaceutical company, recently announced its financial results for the third quarter of 2024. Let’s break down the important details:
Date and Time of Announcement
The Board of Directors convened on February 14, 2024, and the meeting took place from 11:30 a.m. to 1:55 p.m. During this session, they deliberated on various matters, including the financial performance of the company.
Unaudited Financial Results
The Directors approved the unaudited financial results for both the standalone and consolidated entities of Solara Active Pharma Sciences Limited. These results cover the quarter and nine months ending on December 31, 2023. The company adhered to the guidelines set forth by the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.
Key Figures
Here are the essential figures from the financial report:
Revenue: The company reported a total revenue of ₹2.49 billion, reflecting a 37% decrease compared to the same period in 2023.
Net Loss: Solara Active Pharma Sciences faced a net loss of ₹2.75 billion, a significant decline from the ₹4.50 million profit recorded in Q3 2023.
Earnings Per Share (EPS)
The Earnings Per Share (EPS) for Q3 FY24 stands at ₹-59.05, indicating a substantial drop of 49,310.31% year-on-year.
Share Price and Target
While the financial results show challenges, investors should keep an eye on the company’s share price. Solara Active Pharma Sciences has delivered a -1.46% return in the last week, 5.76% return over the past six months, and 8.46% return overall. Analysts and shareholders eagerly await further updates and strategies from the company’s management.
About SOLARA ACTIVE PHARMA SCIENCES :
Solara Active Pharma Sciences Limited is a leading pharmaceutical company with three decades of expertise in pure-play API (Active Pharmaceutical Ingredient) manufacturing. Our mission is to enhance patients’ lives by delivering high-quality products. Here are some key points about Solara:
Background and Focus:
- Three Decades of Experience: Solara has been in the industry for 30 years, consistently striving for excellence.
- Pure-Play API Manufacturer: We specialize in API production, ensuring the quality and efficacy of essential drugs.
Innovation and Entrepreneurship:
- Unifying Technology, Science, and Innovation: Our dynamic and entrepreneurial spirit drives us to create value-based products.
- Customer-Centric Approach: We prioritize customer needs and tailor our offerings accordingly.
Solara Active Pharma Sciences faces headwinds in Q3 2024, but its management’s actions and market dynamics will play a crucial role in shaping its future trajectory. Stay tuned for more updates as the company navigates these challenging times.
Subscribe to Sarkari Result to stay informed. Get the latest celebrity news and detailed movie reviews in real-time. Keep up with the constantly changing world of entertainment with Sarkari Exam.
Disclaimer: Please note that all content and tools on this website are provided for your convenience and are offered “as is” without warranties. The information provided, including any tool-generated output, is for informational purposes only and should not be considered investment advice or guarantees. Exercise caution, seek professional advice, and make independent judgments before acting on any information found on this site.
